Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Akero Therapeutics, Inc.

This article summarizes the most significant insider buying and selling activities reported on Friday for US-listed companies ...

Graham G. Walmsley, a director at Akero Therapeutics, Inc. (NASDAQ:AKRO), recently acquired a significant amount of the company's common stock. According to a recent SEC filing, Walmsley purchased 200 ...

Walmsley, a director at Akero Therapeutics ... The shares are primarily held through Logos Global Master Fund LP and Logos Opportunities Fund IV LP, where Walmsley is a managing member of the ...

Rolph Timothy, the Chief Scientific Officer of Akero Therapeutics Inc . (NASDAQ:AKRO), recently executed a notable share sale, as per the latest SEC filing. The timing is particularly interesting ...

OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. OpenAI’s big rebranding effort brings a new logo and a new typeface, OpenAI sans. Emma Roth is a news writer ...

In this article, we are going to take a look at where Akero Therapeutics Inc (NASDAQ:AKRO) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 ...

In this article, we are going to take a look at where Akero Therapeutics Inc (NASDAQ:AKRO) stands against the other healthcare stocks. The healthcare sector is staging a comeback so far in 2025 after ...

Akero Therapeutics has a 12-month low of $15.32 and a 12-month high of $58.40. The company has a current ratio of 17.25, a quick ratio of 17.25 and a debt-to-equity ratio of 0.05.

On Monday, three logos were revealed to the public, one for each potential nickname, but NHL fans weren't particularly impressed by the latest round of options. Much of the criticism was focused ...

Akero Therapeutics (NASDAQ: AKRO) is part of this group. On Jan. 27, the company's shares soared by 97%, closing the day at $51.71. Unsurprisingly, Akero owes this incredible one-day gain to data ...